Skip to main content

Table 2 Receiver operating characteristic analysis of all biomarkers for predicting response to pulmonary artery catheter guided therapy.

From: Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy

Biomarker AUC 95% CI P
CVP non-response a    
   sST2 0.82 (0.66 - 0.98) < 0.001
   NT-proBNP 0.64 (0.42 - 0.85) 0.10
   hsTnI 0.56 (0.34 - 0.77) 0.30
   eTnI 0.51 (0.29 - 0.74) 0.45
   cys-C 0.70 (0.51 - 0.90) 0.02
   MPO 0.48 (0.24 - 0.72) 0.57
PCWP non-response b    
   sST2 0.68 (0.45 - 0.91) 0.06
   NT-proBNP 0.63 (0.40 - 0.86) 0.13
   hsTnI 0.53 (0.31 - 0.74) 0.41
   eTnI 0.52 (0.29 - 0.74) 0.44
   cys-C 0.62 (0.37 - 0.87) 0.18
   MPO 0.52 (0.31 - 0.74) 0.42
SVR non-responsec    
   sST2 0.59 (0.38 - 0.80) 0.19
   NT-proBNP 0.69 (0.48 - 0.89) 0.04
   hsTnI 0.40 (0.19 - 0.61) 0.82
   eTnI 0.39 (0.17 - 0.61) 0.84
   cys-C 0.45 (0.23 - 0.67) 0.67
   MPO 0.39 (0.18 - 0.60) 0.85
  1. aAUC for CVP non-response was significantly higher for sST2 as compared to cTnI (P = 0.03), and eTnI (P = 0.02), no significant difference between AUC for sST2 and cys-C/NT-proBNP/MPO; bNo significant difference among AUCs for PCWP non-response; cNo significant difference among AUCs for SVR non-response. AUC, area under the curve; CI, confidence intervals; cys-C, cystatin C; eTnI, experimental research prototype Troponin I; hsTnI, highly sensitive Troponin I; MPO, myeloperoxidase; NT-proBNP, amino terminal cleavage fragment of B-type natriuretic peptide; sST2, soluble ST2.